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Two patients, one with and one without preexisting con-
duction system abnormalities, were treated with amio-
darone for refractory ventricular arrhythmias. Electro-
physiologic testing before and during amiodarone therapy
revealed amlodarone-induced HV interval prolongation
and second degree intra-His Wenckebach block with no
change in QRS configuration during atrial pacing at
Amiodarone has been found to be effective in the treatment
of both supraventricular and ventricular tachyarrhythmias
in previous clinical trials (1-7). These and other investi-
gations (8,9) have shown that amiodarone slows the sinus
rate and increases the PR, AH and QT intervals. Exagger-
ation of these effects has resulted in symptomatic sinus
bradycardia and sinus arrest (7,10), atrioventricular (AV)
nodal block (11,12) and ventricular tachyarrhythmias
(7,13-15). There has been less consensus concerning the
effects of amiodarone on the His-Purkinje system (4,6,7),
but Mobitz type II second degree AV block (2) and infra-
His block (7,16) have been reported. Although amiodarone-
induced intra-His delay has been described (17), second
degree block localized to the His bundle has not been doc-
umented. Two cases exhibiting this phenomenon will be
presented.
Case Reports
Patient 1. A 68 year old man with an anteroapical left
ventricular aneurysm secondary to a previous myocardial
infarction was treated with amiodarone because of recurrent
ventricular tachycardia resistant to both conventional and
experimental agents. The baseline electrocardiogram re-
vealed left anterior hemiblock, intraventricular conduction
delay and PR, QRS and QT intervals of 0.16, 0.17 and
0.32 second, respectively. After 20 months of amiodarone
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relatively long cyclelengths. The mechanism responsible
for this phenomenon is unclear. These cases illustrate
that amiodarone can induce distal conduction system
block even in the absence of clinical conduction system
disease in a pattern that mimics atrioventricular nodal
block.
therapy, predominantly at 800 mg daily (a dosage found to
be necessary for arrhythmia control despite near intolerable
noncardiac side effects), PR, QRS and QT intervals were
0.28, 0.18 and 0.56 second, respectively. Intracardiac re-
cordings showed an AH interval of 130 ms and an HV
interval of 135 ms during sinus rhythm with a cycle length
of 885 ms (Fig. IA). Two His deflections were present with
an HH' interval of 60 ms, revealing that a large portion of
the HV interval prolongation was intra-His delay. Atrial
pacing at a cycle length of 800 ms revealed second degree
intra-His block in a 4:3 Wenckebach pattern (Fig. IB).
There was 2:1 intra-His block at a paced cycle length of
750 ms (Fig. lC). A permanent pacemaker was implanted.
Two months after discontinuation of amiodarone therapy,
the HV interval had shortened to 40 ms, and AV block was
not encountered at cycle lengths longer than 400 ms.
Patient 2. A 72 year old man with a history of multiple
syncopal episodes had both spontaneous and inducible non-
sustained ventricular tachycardia. As both conventional and
experimental agents failed to suppress inducibility of tachy-
cardia, amiodarone therapy was begun. After 2 months of
taking amiodarone, 800 mg daily, the patient's electrocar-
diogram revealed a PR interval of 0.20, a QRS interval of
0.09 and a QT interval of 0.40 second. Baseline corre-
sponding values had been 0.17, 0.08 and 0.38 second, re-
spectively. Intracardiac recordings revealed an AH interval
of 90 ms and an HV interval of 50 ms with a single narrow
His deflection in sinus rhythm at a cycle length of 1,110
ms (Fig. 2A). At a paced cycle length of 650 ms, the His
deflection became fragmented (Fig. 2B) with second degree
intra-His block following a 3:2 Wenckebach pattern occur-
ring at a paced cycle length of 600 ms (Fig. 2C). Baseline
electrophysiologic study had shown an AH interval of 75
ms and an HV interval of 40 ms with the onset of AV nodal
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Figure 1. Patient I. Surface electrocardiographic leads I, II and
V1 and intracardiac recordings after 20 months of amiodarone
therapy. A, During sinus rhythm at a cycle length of 885 ms, there
are both intra-His delay (split His potential) and infra-His delay.
B, At an atrial paced cycle length of 800 ms, 4:3 intra-His Wenck-
ebach block occurs. C, At a shorter atrial paced cycle length (750
ms), 2: I intra-His block occurs. HH' = His bundle deflections;
HBE = His bundle electrogram; HRA = high right atrial elec-
trogram; RVA = local right ventricular electrogram at the apex;
TL = time lines. Paper recording speed was 100 mmls.
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Wenckcbach block at a paced cycle length of 460 ms. Arnio-
darone therapy was discontinued.
Validity of the initial and terminal His (H,H') deflec-
tions. The validity of the initial His deflection was estab-
lished in both patients by observing an increase in the AH
interval with decreasing atrial paced cycle length (Fig. 3).
This pattern indicates that incremental conduction delay within
the AV node occurred between the atrial electrogram and
the initial His deflection, and excludes the possibility that
the initial His deflection is either part of the atrial electro-
gram 01 artifact. This is particularly relevant to the record-
ings from Patient I, whose initial His deflection is slurred,
perhaps reflecting the diseased state of his His-Purkinje tis-
sue. Similarly, the validity of the terminal His deflection
(H') was established by observing a relatively constant H'V
interval despite decreasing atrial paced cycle length, and by
finding the H'V interval to be consistently greater than 30
ms (Fig. 3). The possibility that H' represents either right
bundle branch potential or artifact is thereby excluded.
Discussion
The most consistently described effects of amiodarone
have been on the sinus node and the atrioventricular (AY)
node, with findings concerning His-Purkinje tissue being
less uniform (4,6,7). Previously described AY block has
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Figure 2. Patient 2. Surface electrocardiographic leads I and II
and intracardiac recordings after 2 months of amiodarone therapy.
A, Sinus rhythm, cycle length I, 110 ms, shows normal AH and
HV intervals and a single His deflection. B, Atrial pacing at a
cycle length of 650 ms produces intra-His delay and a fragmented
His deflection. C, A 3:2 intra-His Wenckebach block occurs at a
shorter atrial paced cycle length of 600 ms. Abbreviations as in
Figure I.
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Figure 3. Intracardiac conduction intervals at varying atrial paced
cycle lengths. Both patients demonstrate a progressive increase in
AH intervals at shorter cycle lengths, whereas H'V intervals remain
constant. Second degree intra-His block is first encountered at a
paced cycle length of 800 ms in Patient 1 and at a paced cycle
length of 600 ms in Patient 2.
been either AV nodal block (11,12) or infra-Hisblock (2,7, 16)
occurring in patients with preexisting conduction system
disease. These two cases demonstrate that: 1) amiodarone
can cause AV block within the His bundle, and 2) amio-
darone can cause distal AV block in the absence of apparent
preexisting conduction system disease, The cellular mech-
anisms responsible for this effect are speculative and may
differ in patients with and without preexisting His-Purkinje
tissue abnormalities.
Mechanism of amiedarone-induced block. The major
effect of amiodarone on cellular action potentials is a pro-
longation of action potential duration (8). More recently,
the possibility that amiodarone may also affect sodium and
calcium channels has been raised. Using voltage clamp tech-
niques, Mason et al. (18) produced evidence that amioda-
rone depresses partially inactivated sodium channels. Such
an effect could have been responsible for the intra-His block
in Patient 2, who had a normal electrocardiogram and HV
interval suggesting normal sodium channel-dependent His-
Purkinje tissue. Depression of the sodium channel could
have then caused the observed decremental conduction pre-
ceding block, either because of emergence of a calcium-
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dependent mechanism or because of severe depression of
the sodium channel.
Depression of the calcium channel by amiodarone has
been recently suggested (12) as underlying the drug's action
on the sinus node (9). Similar depression may cause dete-
rioration of conduction in diseased His-Purkinje tissue, as
ischemic proximal His-Purkinje tissue may show electro-
physio logic characteristics strongly suggestive of calcium
channel dependency (19). An effect on the slow channel
may have produced the intra-His block in Patient I, who
had preexisting left anterior hemiblock and intraventricular
conduc lion delay and a previous anterior myocardial
infarct ion.
Conclusion. Significant AV conduction abnormalities
can oc; .ur with amiodarone therapy, even in patients without
preexisting conduction system disease, These effects may
not be limited solely to the AV node. His bundle recordings
may be required to define the site of block and to direct
further therapeutic decisions, as intra-His Wenckebach is
otherwise indistinguishable from AV nodal Wenckebach
block, Clarification of the effect of amiodarone on various
ionic cnannels is needed.
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